NEW YORK (GenomeWeb) – Quanterix on Thursday announced the completion of an $8.5 million private placement led by T. Rowe Price.

The funding is a follow-on to the firm's Series D financing round, which raised $46 million in March 2016, and will be used to develop new instruments, expand Quanterix's assay menu, and "meet global demand for the company's proprietary platform across therapeutic markets," it said.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

British Nobel laureates and Fields Medal winners warn that a 'hard' Brexit could harm science across the UK, the Guardian reports.

Vox reports on inequities in genetic research and efforts to address them.

The New York Times reports that Arizona State University's Lawrence Krauss is retiring following allegations of sexual misconduct.

In PNAS this week: de novo NUS1 mutations linked to Parkinson's disease risk, candidate hepatocellular carcinoma drivers, and more.